GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS: 87 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
87
Total FAERS Reports
12 (13.8%)
Deaths Reported
19
Hospitalizations
87
As Primary/Secondary Suspect
2
Life-Threatening
First Report: 20200101 · Latest Report: 20230922
What Are the Most Common GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS Side Effects?
#1 Most Reported
Disease progression
28 reports (32.2%)
#2 Most Reported
Lymphoma
17 reports (19.5%)
#3 Most Reported
Cytokine release syndrome
16 reports (18.4%)
All GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 28 | 32.2% | 0 | 1 |
| Lymphoma | 17 | 19.5% | 0 | 0 |
| Cytokine release syndrome | 16 | 18.4% | 5 | 8 |
| Off label use | 14 | 16.1% | 3 | 2 |
| Neutropenia | 9 | 10.3% | 1 | 1 |
| Plasma cell myeloma refractory | 9 | 10.3% | 0 | 0 |
| Pyrexia | 8 | 9.2% | 0 | 2 |
| Atrial fibrillation | 5 | 5.8% | 0 | 0 |
| Covid-19 | 5 | 5.8% | 4 | 4 |
| Death | 5 | 5.8% | 5 | 3 |
| Malignant neoplasm progression | 5 | 5.8% | 0 | 0 |
Who Reports GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS Side Effects? Age & Gender Data
Gender: 49.2% female, 50.8% male. Average age: 52.7 years. Most reports from: DE. View detailed demographics →
Is GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2020 | 6 | 1 | 4 |
| 2021 | 3 | 0 | 0 |
| 2022 | 12 | 5 | 5 |
| 2023 | 3 | 2 | 2 |
What Is GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS Used For?
| Indication | Reports |
|---|---|
| Diffuse large b-cell lymphoma | 36 |
| Plasma cell myeloma | 12 |
| Plasma cell myeloma refractory | 5 |
Official FDA Label for GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS
Official prescribing information from the FDA-approved drug label.